Andere Sprachen Arrowhead Pharmaceuticals, Inc.

Aktien

A2AGYB

US04280A1007

ARWR

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 02.05.2024			% 5 Tage	% 1. Jan.
24,13 ^USD	+4,14 %		+10,33 %	-21,14 %

24.04.	Arrowhead Pharmaceuticals startet Phase 1/2a-Studie mit ARO-CFB zur Behandlung von komplementvermittelten Nierenerkrankungen	CI
07.04.	Arrowhead Pharmaceuticals, Inc. gibt neue Phase-2-Daten zu Plozasiran bekannt, die in JAMA Cardiology veröffentlicht und auf der 73. jährlichen wissenschaftlichen Tagung & Expo des American College of Cardiology vorgestellt wurden	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma	02.05.
Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences	29.04.
Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars	26.04.
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results	24.04.
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease	24.04.
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease	24.04.
Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo	07.04.
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo	07.04.
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	01.04.
Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data	25.03.
Arrowhead Pharmaceuticals, Inc. Initiates Expanded Access Program for Plozasiran	25.03.
Arrowhead Doses First Subjects in Phase 1/2a Study of Myotonic Dystrophy Treatment; Shares Rise	08.03.
Arrowhead Pharmaceuticals : 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference View Presentation	08.03.
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy	08.03.
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy	08.03.
Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences	04.03.
Certain Restricted Stock Units of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-MAR-2024.	03.03.
Certain Common Stock of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-MAR-2024.	03.03.
Arrowhead Pharmaceuticals, Inc. Appoints Hongbo Lu as Independent Director, Effective April 1, 2024	22.02.
Sector Update: Health Care Stocks Firmer Late Afternoon	07.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Arrowhead Pharmaceuticals, Inc.

Aktien

A2AGYB

US04280A1007

ARWR

Andere Sprachen

Filter